Halma PLC
Open
SectorIndustrials
3,614 0.61
Overview
Share price change
24h
Min
3568
Max
3656
Income | -1.3M 186M |
|---|---|
Sales | 108M 1.3B |
P/E Sector Avg | 37.225 38.75 |
EPS | 0.553 |
Dividend yield | 0.69 |
Profit margin | 13.793 |
Employees | 9,000 |
EBITDA | -2.5M 315M |
Dividend yield Sector Avg | 0.69% 2.12% |
|---|---|
Next Earnings | 19 Nov 2026 |
Market Cap | -4.3B 14B |
|---|---|
Previous open | 3613.39 |
Previous close | 3614 |
News Sentiment
By Acuity
67%
33%
337 / 403 Industrials
Halma PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Halma PLC Forecast
Sentiment
By Acuity
337 / 403 Industrials
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Halma PLC
Halma plc, together its subsidiaries, provides technology solutions in the safety, health, and environmental markets in the United States, Mainland Europe, the United Kingdom, the Asia Pacific, Africa, the Middle East, and internationally. It operates through three segments: Safety, Environmental & Analysis, and Healthcare. The Safety segment provides products that protect people, assets and infrastructure, and electrical systems which is used in public and commercial spaces and in industrial and logistics operations. This segment serves Fire Safety, Power Safety, Industrial Safety, and Urban Safety markets. The Environmental & Analysis segment offers optical, optoelectronic, and spectral imaging systems; environmental monitoring; analysis of air quality, gases, and water; detection of hazardous gases; and water analysis & treatment systems. It serves the optical analysis, water analysis and treatment, and environmental monitoring markets. The Healthcare segment provides components, devices and systems that provide information and analytics to understand patient health and make decisions across the continuum of care; technologies and solutions to enable in-vitro diagnostic systems and life-science discoveries and development; and technologies that enable treatment across clinical specialties, as well as critical fluidic components used by medical diagnostics and original equipment manufacturers. This segment serves the life sciences, health assessment and analytics, and therapeutic solutions market. The company was incorporated in 1894 and is headquartered in Amersham, the United Kingdom.